Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy|
|Citation:||Leukemia and Lymphoma, 2021; 62(5):1157-1166|
|Publisher:||Taylor & Francis|
|Susan L. Heatley, Kartini Asari, Caitlin E. Schutz, Tamara M. Leclercq, Barbara J. McClure, Laura N. Eadie , Timothy P. Hughes, David T. Yeung and Deborah L. White|
|Abstract:||Acute lymphoblastic leukemia remains a leading cause of cancer-related death in children. Furthermore, subtypes such as Ph-like ALL remain at high-risk of relapse, and treatment resistance remains a significant clinical issue. The patient-derived Ph-like ALL RANBP2-ABL1 fusion gene was transduced into Ba/F3 cells and allowed to become resistant to the tyrosine kinase inhibitors (TKIs) imatinib or dasatinib, followed by secondary resistance to ponatinib. RANBP2-ABL1 Ba/F3 cells developed the clinically relevant ABL1 p.T315I mutation and upon secondary resistance to ponatinib, developed compound mutations, including a novel ABL1 p.L302H mutation. Significantly, compound mutations were targetable with a combination of asciminib and ponatinib. In-vitro modeling of Ph-like ALL RANBP2-ABL1 has identified kinase domain mutations in response to TKI treatment, that may have important clinical ramifications. Early detection of mutations is paramount to guide treatment strategies and improve survival in this high-risk group of patients.|
|Keywords:||Acute lymphoblastic leukemia; Ph-like ALL; TKI resistance; asciminib; ABL-class fusions|
|Rights:||© 2020 Informa UK Limited, trading as Taylor & Francis Group|
|Appears in Collections:||Aurora harvest 4|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.